Recent Updates
Recently added Catalysts
PCRX Negative Sentiment Score: 20/100

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Key Takeaway: ClaimsFiler has alerted investors in Pacira BioSciences, Inc. about a deadline to file lead plaintiff applications in a securities class action lawsuit. This lawsuit pertains to alleged failures by the company to disclose material information between August 2, 2023, and August 8, 2024. Following a significant patent infringement ruling against its Exparel product, which constitutes a large portion of the company's revenue, Pacira's stock experienced a steep decline of over 47%. The legal action is currently pending in the United States District Court for New Jersey.

Market Sentiment Analysis

CONCERNS & RISKS

  • Pacira BioSciences is facing a securities class action lawsuit.
  • The company's stock price fell over 47% following unfavorable patent ruling.
  • Investors are reminded of a deadline to file as lead plaintiffs in the lawsuit.
  • The class action relates to undisclosed material information that violated federal securities laws.

Full Press Release Details

NEW ORLEANS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company’s securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Pacira investors should visit us at https://claimsfiler.com/cases/nasdaq-pcrx-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Pacira and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 9, 2024, the Company released the results of its lawsuit against eVenus for patent infringement relating to its Exparel product, which accounts for approximately 80% of the Company’s revenue, disclosing that the U.S. District Court for the District of New Jersey had “found that the company’s U.S. Patent No. 11,033,495 is not valid,” and, thus, eVenus was not infringing on anything. On this news, the price of Pacira’s shares fell over 47%, from a closing price of $22.36 per share on August 8, 2024 to a low of $11.70 per share on August 9, 2024.
The case is Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline to file a lead plaintiff application?

The deadline is March 14, 2025, for filing lead plaintiff applications.

What is the class period for the Pacira lawsuit?

The class period is from August 2, 2023, to August 8, 2024.

What caused Pacira's share price to drop significantly?

The share price fell over 47% after a patent ruling against Pacira on August 9, 2024.

Which law firm is involved in this case?

The law firm involved is Kahn Swick & Foti, LLC.

How can investors get more information from ClaimsFiler?

Investors can visit ClaimsFiler.com or call toll-free at 844-367-9658 for info.

Last updated: Feb 6, 2025